What are the guidelines for treatment of chronic HCV infection in non-NS5A inhibitor, sofosbuvir-containing regimen, treatment-experienced genotype 1 patients without cirrhosis?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print
Answer

HCV genotype 1 non-NS5A inhibitor, sofosbuvir-containing regimen, treatment-experienced patients without cirrhosis

Recommended regimens

  • Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for 12 weeks for genotype 1a patients
  • Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) for 12 weeks, regardless of HCV subtype
  • Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks for genotype 1b patients

Alternative regimen

  • Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin, except in simeprevir failures, for 12 weeks

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!